Essential Science

Edzell, July 16 2007 - Essential Science Ltd is working with BioAgency AG, Hamburg, Germany, to identify licensing opportunities for BioAgency's novel, proprietary bacterial target and screening assay.

BioAgency's subsidiary, Novologix, has discovered that a ubiquitous, well characterized bacterial protein also plays a pivotal role in the formation of the bacterial cytoskeleton. In addition Novologix have developed and validated a screening assay which has been used to identify novel small molecule compounds with bactericidal activity. The ubiquitous nature of this protein in bacteria and its absence in eukaryotes, makes this a potentially important target for novel antibiotics active against both G-ve and G+ve bacteria.

There is continuing unmet medical need for novel antibiotics against resistant bacterial strains and increasing interest in antibiotics against G-ve organisms for which there are few programs in development.

For further information, contact:

Steve Smith, Director :: +33 545 31 55 90 :: steve@essentialscience.co.uk

About Essential Science

Essential Science Ltd supports technology clients in the development and exploitation of new technologies across the Life Science marketplace. As the number of available technologies grows and client success becomes increasingly dependent on the identification and exploitation of the right technologies, its experienced team, supported by an extensive associate network, is focused on establishing the partnerships that bring client technologies to market faster and more effectively.

Enquiries :: Neil Murray :: +44 1356 648941 :: neil@essentialscience.co.uk

Date :: Monday 16 July 2007